Rhythm Pharmaceuticals Inc (RYTM)
59.03
-0.33
(-0.56%)
USD |
NASDAQ |
Nov 21, 16:00
61.00
+1.97
(+3.34%)
After-Hours: 05:12
Rhythm Pharmaceuticals Revenue (Quarterly): 33.25M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 33.25M |
| June 30, 2024 | 29.08M |
| March 31, 2024 | 25.97M |
| December 31, 2023 | 24.23M |
| September 30, 2023 | 22.50M |
| June 30, 2023 | 19.22M |
| March 31, 2023 | 11.47M |
| December 31, 2022 | 8.79M |
| Date | Value |
|---|---|
| September 30, 2022 | 4.284M |
| June 30, 2022 | 9.066M |
| March 31, 2022 | 1.498M |
| December 31, 2021 | 1.817M |
| September 30, 2021 | 1.028M |
| June 30, 2021 | 0.274M |
| March 31, 2021 | 0.035M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.035M
Minimum
Mar 2021
33.25M
Maximum
Sep 2024
12.83M
Average
9.066M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 11.44B |
| TG Therapeutics Inc | 83.88M |
| Regeneron Pharmaceuticals Inc | 3.721B |
| Voyager Therapeutics Inc | 24.63M |
| Krystal Biotech Inc | 83.84M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -43.64M |
| Total Expenses (Quarterly) | 77.14M |
| EPS Diluted (Quarterly) | -0.73 |
| Enterprise Value | 3.329B |
| Gross Profit Margin (Quarterly) | 88.49% |
| Profit Margin (Quarterly) | -131.2% |
| Earnings Yield | -7.34% |
| Normalized Earnings Yield | -7.530 |